JBIO highlights JADE101 progress in IgA nephropathy pipeline expansion
Jade Bioscience says JADE101 shows best-in-class potential in IgA nephropathy and rapid clinical progress, alongside three advanced autoimmune therapeutics. The company cites strong financials and strategic trial designs to expand into additional indications and support efficient market entry.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.